RenovaCare (RenovaCare) Debt-to-Asset : 0.76 (As of Sep. 2022)

View and export this data going back to . Start your Free Trial

What is RenovaCare Debt-to-Asset?

RenovaCare's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $0.00 Mil. RenovaCare's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $0.80 Mil. RenovaCare's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2022 was $1.06 Mil. RenovaCare's debt to asset for the quarter that ended in Sep. 2022 was 0.76.

RenovaCare Debt-to-Asset Historical Data

The historical data trend for RenovaCare's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RenovaCare Debt-to-Asset Chart

RenovaCare Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Debt-to-Asset

Get a 7-Day Free Trial

0.34

0.01

RenovaCare Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Debt-to-Asset	Get a 7-Day Free Trial															0.01	0.01	0.27	0.56	0.76

Competitive Comparison of RenovaCare's Debt-to-Asset

For the Biotechnology subindustry, RenovaCare's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RenovaCare's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RenovaCare's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where RenovaCare's Debt-to-Asset falls into.

RenovaCare Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

RenovaCare's Debt-to-Asset for the fiscal year that ended in Dec. 2021 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.03	+	0)	/	3.652
	=	0.01

RenovaCare's Debt-to-Asset for the quarter that ended in Sep. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0.8)	/	1.055
	=	0.76

RenovaCare (OTCPK:RCAR) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

RenovaCare Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of RenovaCare's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

RenovaCare (RenovaCare) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RenovaCare Inc (OTCPK:RCAR) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

9375 East Shea Boulvard, Suite 107-A, Scottsdale, AZ, USA, 85260

Website

https://www.renovacareinc.com

RenovaCare Inc is a biotechnology company focusing on the acquisition, research, development and commercialization of autologous cellular therapies that can be used for medical and aesthetic applications. The company's initial products under development target skin. It offers treatment methodology for cell isolation for the regeneration of human skin cells, along with a medical-grade liquid spraying device and associated equipment (the SkinGun). RenovaCare is evaluating the efficacy and potential of SkinGun, in combination with a cell isolation method, in the treatment of tissue that has been subject to severe trauma. Geographically all the activities are functioned through the region of United States.

Executives

Patsy Trisler	officer: Vice President	430 PARK AVENUE, SUITE 702, NEW YORK NY 10022
Thomas Bold	officer: President & CEO	430 PARK AVENUE, SUITE 702, NEW YORK NY 10022
Joseph Sierchio	director	430 PARK AVENUE, SUITE 702, NEW YORK NY 10022
Kenneth Kirkland	director	430 PARK AVENUE, SUITE 702, NEW YORK NY 10022
Rhonda Beth Rosen	director, officer: President & CEO	43 DICKINSON ROAD, BASKING RIDGE NJ 07920
1420525 Alberta Ltd.	10 percent owner	1628 WEST 1ST AVENUE, SUITE 216, VANCOUVER A1 V6J1G1
David E Jenkins	director	406 NORTH HERMOSA DRIVE, PALM SPRINGS CA 92262
Antonino G Cacace	director, officer: President	CRUD-Y-GWYNT, CASWELL BAY, SWANSEA X0 SA3 3BU
Jeet Sidhu	director	5667 SUNRISE CRESCENT WEST, SURREY, BC A1 V3S 7M4
Derek Cooper	officer: President/ CEO
Frank J Fabio	officer: CFO/Sec.(Resigned 1/9/2009)	670 BROADWAY, MASSAPEQUA NY 11758
Christian F Hudson	director	33 CHURCHILL ROAD, TENAFLY NJ 07670
Harmel S Rayat	director, 10 percent owner	700 - 688 WEST HASTINGS STREET, VANCOUVER A1 V6B 1P1
Stanley Wong	officer: President/CEO
Terri Dumoulin	director, officer: Secretary/Treasurer